|
|||
168 HR BuTrans 0.015 MG/HR Transdermal System |
What was the prescribed dosage? |
Here is the some steps to help you to save money on 168 HR BuTrans 0.015 MG/HR Transdermal System purchase.
Read drug prescription
What is 168 HR BuTrans 0.015 MG/HR Transdermal System
168 HR BuTrans 0.015 MG/HR Transdermal System is an opioid medication. An opioid is sometimes called a narcotic.168 HR BuTrans 0.015 MG/HR Transdermal System oral is used to treat narcotic addiction. 168 HR BuTrans 0.015 MG/HR Transdermal System sublingual is not for use as a pain medication.
168 HR BuTrans 0.015 MG/HR Transdermal System may also be used for purposes not listed in 168 HR BuTrans 0.015 MG/HR Transdermal System guide.
168 HR BuTrans 0.015 MG/HR Transdermal System side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.Like other narcotic medicines, 168 HR BuTrans 0.015 MG/HR Transdermal System can slow your breathing. Death may occur if breathing becomes too weak.
Call your doctor at once if you have:
- weak or shallow breathing;
- a light-headed feeling, like you might pass out;
- confusion, unusual thoughts or behavior; or
- nausea, upper stomach pain, itching, loss of appetite, dark urine, clay-colored stools, jaundice.
Common side effects may be more likely to occur, such as:
- constipation, nausea, vomiting;
- headache;
- increased sweating;
- sleep problems (insomnia); or
- pain anywhere in your body.
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
See also: Side effects (in more detail)
168 HR BuTrans 0.015 MG/HR Transdermal System dosing
Usual Adult Dose for Opiate Dependence:
Induction dose:-Day 1: 8 mg sublingually once a day
-Day 2: 16 mg sublingually once a day
Maintenance dose: 4 to 24 mg/day; dose adjustments may be made in increments/decrements of 2 or 4 mg to a level that suppresses opioid withdrawal symptoms and holds the patient in treatment.
Comments:
-To avoid precipitating withdrawal during induction, initiation should occur when clear signs of withdrawal are evident, preferably when moderate objective signs of opioid withdrawal appear.
-Following induction, combination buprenorphine/naloxone is preferred; use of 168 HR BuTrans 0.015 MG/HR Transdermal System alone should be limited to those patients who cannot tolerate naloxone.
Use: For the treatment of opioid dependence, preferably induction only. This drug should be used as part of a complete treatment plan to include counseling and psychosocial support.
Usual Adult Dose for Pain:
Parenteral:Initial dose: 0.3 mg deep IM or slow IV ; may repeat initial dose once after 30 to 60 minutes if required
Maintenance dose: 0.3 mg deep IM or slow IV at up to 6-hour intervals as needed
Maximum dose: 0.3 mg (IV) or 0.6 mg (IM)
Comments:
-Use extra caution with IV administration, especially the first dose
Use: For the relief of moderate to severe pain
Usual Adult Dose for Chronic Pain:
Individualize dosing taking into account prior analgesic treatment; 7.5 mcg, 10 mcg, 15 mcg, and 20 mcg/hr patches are for opioid-experienced patients only.-As first opioid analgesic: Initiate with 5 mcg/hr patch applied transdermally every 7 days
Conversion from Other Opioids to 168 HR BuTrans 0.015 MG/HR Transdermal System:
-Discontinue all other around-the-clock opioid drugs when initiating therapy
For patients whose prior total opioid dose is less than 30 mg/day of oral morphine equivalents:
-Initiate with 5 mcg/hr patch applied transdermally every 7 days at next dosing interval
For patients whose prior total opioid dose is between 30 and 80 mg/day of oral morphine equivalents:
-Taper around-the-clock opioids for up to 7 days to no more than 30 mg/day of oral morphine equivalents, then initiate with 10 mcg/hr patch applied transdermally every 7 days starting at the next dosing interval; may use short-acting analgesics as needed until analgesic efficacy is attained.
For patients whose prior total opioid dose is greater than 80 mg/day of oral morphine equivalents:
-Consider use of an alternate analgesic as 20 mcg/hr patch may not provide adequate analgesia
Conversion from Methadone:
-The ratio between methadone and other opioid agonists may vary widely due to its long half-life and accumulation in the plasma; close monitoring is of particular importance.
Titration: Individually titrate to a dose that provides adequate analgesia and minimizes adverse reactions; minimal titration interval is 72 hours
Maximum dose: 20 mcg/hr due to risk of QTc interval prolongation
Comments:
-Monitor patients closely for respiratory depression, especially within 24 to 72 hours after initiating therapy.
-If pain level increases after dose stabilization, attempt to identify source of increased pain before increasing 168 HR BuTrans 0.015 MG/HR Transdermal System dose
-Do not abruptly discontinue; use a gradual downward titration every 7 days, may consider introduction of an immediate-release opioid.
Use: For the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate.
Usual Pediatric Dose for Pain:
Parenteral:13 years or older:
Initial dose: 0.3 mg deep IM or slow IV ; may repeat initial dose once after 30 to 60 minutes if required
Maintenance dose: 0.3 mg deep IM or slow IV at up to 6-hour intervals as needed
Maximum dose: 0.3 mg
2 to 12 years: 2 to 6 mcg/kg IM or slow IV every 4 to 6 hours; some patients may not need to be remedicated for 6 to 8 hours
Comments:
-Fixed interval or round the clock dosing should not be used until the proper inter-dose interval has been established.
-Use extra caution with IV administration, especially the first dose
Use: For the relief of moderate to severe pain
Usual Pediatric Dose for Opiate Dependence:
Aged 16 years or older:Induction dose:
-Day 1: 8 mg sublingually once a day
-Day 2: 16 mg sublingually once a day
Maintenance dose: 4 to 24 mg/day; dose adjustments may be made in increments/decrements of 2 or 4 mg to a level that suppresses opioid withdrawal symptoms and holds the patient in treatment.
Comments:
-To avoid precipitating withdrawal during induction, initiation should occur when clear signs of withdrawal are evident, preferably when moderate objective signs of opioid withdrawal appear.
-Following induction, combination buprenorphine/naloxone is preferred; use of 168 HR BuTrans 0.015 MG/HR Transdermal System alone should be limited to those patients who cannot tolerate naloxone.
Use: For the treatment of opioid dependence, preferably induction only. This drug should be used as part of a complete treatment plan to include counseling and psychosocial support.
Select the most affordable brand or generic drug
| Strength | Quantity | Price, USD | Country |
| 168 HR BuTrans 0.005 MG/HR Transdermal System | |||
| 168 HR BuTrans 0.0075 MG/HR Transdermal Patch | |||
| 168 HR Buprenorphine 0.005 MG/HR Transdermal Patch [BuTrans] | |||
| 168 HR Buprenorphine 0.005 MG/HR Transdermal System [BuTrans] | |||
| 168 HR Buprenorphine 0.01 MG/HR Transdermal Patch | |||
| 168 HR Buprenorphine 0.01 MG/HR Transdermal System | |||
| 168 HR Buprenorphine 0.015 MG/HR Transdermal Patch [BuTrans] | |||
| 168 HR Buprenorphine 0.015 MG/HR Transdermal System [BuTrans] | |||
| Berotam | |||
| BuTrans 10 MCG/HR Weekly Transdermal Patch | |||
| Buepron | |||
| Bunogesic | |||
| 0 .3mg/1ml | 1 ml | $0.15 | |
| Bunogesic 0.3 mg Injection | $0.15 | ||
| Bunogesic 0.6 mg Injection | $0.12 | ||
| Bupaq | |||
| Bupensan | |||
| Bupr?norphine Arrow | |||
| Bupr?norphine Biogaran | |||
| Buprenex (injection - Buprenex) | |||
| 0 .3mg/ml | 10 solution | $115.88 | USA |
| Buprenodale | |||
| Buprenorfin Acino | |||
| Buprenorfin Evolan | |||
| Buprenorfina Actavis | |||
| Buprenorfina Azevedos | |||
| Buprenorfina Goldfarma | |||
| Buprenorfina Molteni | |||
| Buprenorfina Sigillata | |||
| Buprenorfine | |||
| Buprenorfine Fisher | |||
| Buprenorfine Mylan | |||
| Buprenorphin AWD | |||
| Buprenorphin Teva | |||
| Buprenorphin dura | |||
| Buprenorphin-neuraxpharm | |||
| Buprenorphine 1.8 MG/ML Injectable Solution [Simbadol] | |||
| Buprenorphine Actavis | |||
| Buprenorphine BMM Pharma | |||
| Buprenorphine Bluefish | |||
| Buprenorphine Hydrochloride Hospira | |||
| Buprenorphine Martindale | |||
| Buprenorphine Orifarm | |||
| Buprenotex | |||
| Buprigesic (2 ml) | |||
| Buprigesic 0.3mg AMP / 1mlx10 | $1.51 | ||
| BUPRIGESIC inj 0.3 mg x 1ml | $2.15 | Neon Labs | |
| BUPRIGESIC Injection / 0.3mg per ml (10x2ml units) | $2.52 | Neon Laboratories | |
| Buprénorphine Arrow | |||
| Buprénorphine EG | |||
| Butrans 10 MCG/HR 7 Day Transdermal System | |||
| Butrans 20 MCG/HR 7 Day Transdermal Patch | |||
| Butrans 5 MCG/HR 7 Day Transdermal System | |||
| Butrans patch | |||
| CRAS | |||
| Cras 25+1.25 Tablet | $0.06 | ||
| Cras Capsule/ Tablet / 25mg-1.25mg (10 units) | $0.62 | Systopic Laboratories | |
| Feliben | |||
| Hapoctasin | |||
| Loxina | |||
| Morgesic | |||
| 0 .3mg/1ml | 1 ml | $0.20 | |
| Nermin | |||
| Nopan | |||
| Pentorel (2 ml) | |||
| 0 .3mg/1ml | 2 ml | $0.06 | |
| 0 .3mg/1ml | 2 ml | $0.10 | |
| Pentorel 0.3mg/ml Injection | $0.05 | Khandelwal Laboratories Pvt Ltd | |
| 0 .3 mg x 1 mL x 1's | $0.06 | ||
| Pentorel 0.3mg/ml INJ / 1ml | $0.06 | ||
| PENTOREL inj 0.3 mg x 1 mL x 1ml | $0.06 | Khandelwal | |
| 0 .3 mg x 1 mL x 2ml | $0.10 | ||
| Pentorel 0.3mg/ml INJ / 2ml | $0.10 | ||
| PENTOREL inj 0.3 mg x 1 mL x 2ml | $0.10 | Khandelwal | |
| Prenorvine | |||
| Simbadol | |||
| Simbadol 1.8 MG/ML Injectable Solution | |||
| Subutex | |||
| Subutex 2 mg x 7's | $30.80 | ||
| Subutex 8 mg x 7's | $92.40 | ||
| TEMGESIC | |||
| Temgesic 0.3 mg/1 mL x 1 mL x 5's | $52.13 | ||
| Temgesic 0.2 mg x 50's | $57.35 | ||
| Talgesic | |||
| 0 .3mg/2ml | 2 ml | $0.22 | |
| Talgesic 0.6 mg Injection | $0.11 | ||
| Temg?sic | |||
| Tidigesic (1 ml) | |||
| 0 .3 mg x 1 mL x 1ml | $0.16 | ||
| TIDIGESIC 0.3MG INJECTION 1 vial(s) (1 ML injection each) | $0.17 | Sun Pharma Laboratories Ltd | |
| TIDIGESIC Injection / 0.3mg per ml (2ml units) | $0.21 | Sun Pharmaceuticals | |
| Tidigesic 0.2mg SL-TAB / 10 | $0.35 | ||
| Transtec | |||
| Vetergesic | |||
| Zalba | |||
| buprenorphine (implant) | |||
| Subutex 8 mg Sublingual Tabs | $10.20 | ||
| Buprenorphine 0.3 mg/ml vial | $2.96 | ||
| Buprenorphine 2 mg tablet sl | $4.14 | ||
| Buprenex 0.3 mg/ml Solution (1 Box Contains Five 1ml Box) | $46.39 | ||
| Subutex 2 mg tablet sl | $5.00 | ||
| Subutex 2 mg Sublingual Tabs | $5.59 | ||
| Buprenex 0.3 mg/ml ampul | $6.96 | ||
| Buprenorphine 8 mg tablet sl | $7.74 | ||
| Subutex 8 mg tablet sl | $9.40 | ||
| buprenorphine (injection - Sublocade) | |||
| Subutex 8 mg Sublingual Tabs | $10.20 | ||
| Buprenorphine 0.3 mg/ml vial | $2.96 | ||
| Buprenorphine 2 mg tablet sl | $4.14 | ||
| Buprenex 0.3 mg/ml Solution (1 Box Contains Five 1ml Box) | $46.39 | ||
| Subutex 2 mg tablet sl | $5.00 | ||
| Subutex 2 mg Sublingual Tabs | $5.59 | ||
| Buprenex 0.3 mg/ml ampul | $6.96 | ||
| Buprenorphine 8 mg tablet sl | $7.74 | ||
| Subutex 8 mg tablet sl | $9.40 | ||
| buprenorphine 1.8 MG/ML (as buprenorphine hydrochloride 1.94 MG/ML) Injectable Solution | |||
| buprenorphine 20 MCG/HR Weekly Transdermal Patch | |||
| buprenorphine 5 MCG/HR Weekly Transdermal Patch | |||
References
- Dailymed."Buprenorphine: dailymed provides trustworthy information about marketed drugs in the united states. dailymed is the official provider of fda label information (package inserts).". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
- Dailymed."Butrans (buprenorphine) patch, extended release [purdue pharma lp]". https://dailymed.nlm.nih.gov/dailym... (accessed August 28, 2018).
- "Buprenorphine". https://pubchem.ncbi.nlm.nih.gov/co... (accessed August 28, 2018).
168 HR BuTrans 0.015 MG/HR Transdermal System - Frequently asked Questions
Can 168 HR BuTrans 0.015 MG/HR Transdermal System be stopped immediately or do I have to stop the consumption gradually to ween off?
In some cases, it always advisable to stop the intake of some medicines gradually because of the rebound effect of the medicine.
It's wise to get in touch with your doctor as a professional advice is needed in this case regarding your health, medications and further recommendation to give you a stable health condition.
What other drugs will affect 168 HR BuTrans 0.015 MG/HR Transdermal System?
Using 168 HR BuTrans 0.015 MG/HR Transdermal System with other drugs that make you sleepy or slow your breathing can cause dangerous or life-threatening side effects. Ask your doctor before using 168 HR BuTrans 0.015 MG/HR Transdermal System with a sleeping pill, a sedative or tranquilizer, other narcotic pain medicine, muscle relaxer, or medicine for anxiety, depression, or seizures.
Other drugs may interact with 168 HR BuTrans 0.015 MG/HR Transdermal System, including prescription and over-the-counter medicines, vitamins, and herbal products. Tell each of your health care providers about all medicines you use now and any medicine you start or stop using.
Who should not take 168 HR BuTrans 0.015 MG/HR Transdermal System?
You should not use this medicine if you are allergic to 168 HR BuTrans 0.015 MG/HR Transdermal System, or if you have used another narcotic drug within the past 4 hours.
To make sure 168 HR BuTrans 0.015 MG/HR Transdermal System is safe for you, tell your doctor if you have:
-
any type of breathing problem or lung disease;
-
curvature of the spine that affects breathing;
-
liver disease ;
-
enlarged prostate, urination problems;
-
problems with your gallbladder, adrenal gland, or thyroid;
-
a history of head injury, brain tumor, or seizures; or
-
a history of drug abuse, alcohol addiction, or mental illness.
It is not known whether this medicine will harm an unborn baby. If you use 168 HR BuTrans 0.015 MG/HR Transdermal System while you are pregnant, your baby could become dependent on the drug. This can cause life-threatening withdrawal symptoms in the baby after it is born. Babies born dependent on habit-forming medicine may need medical treatment for several weeks. Tell your doctor if you are pregnant or plan to become pregnant.
168 HR BuTrans 0.015 MG/HR Transdermal System can pass into breast milk and may harm a nursing baby. You should not breast-feed while you are using 168 HR BuTrans 0.015 MG/HR Transdermal System.
Do not give this medication to a child.
How should I take 168 HR BuTrans 0.015 MG/HR Transdermal System?
Follow all directions on your prescription label. 168 HR BuTrans 0.015 MG/HR Transdermal System can slow or stop your breathing. Never use 168 HR BuTrans 0.015 MG/HR Transdermal System in larger amounts, or for longer than prescribed. Tell your doctor if the medicine seems to stop working as well in relieving your pain.
168 HR BuTrans 0.015 MG/HR Transdermal System may be habit-forming, even at regular doses. Never share this medicine with another person, especially someone with a history of drug abuse or addiction. MISUSE OF NARCOTIC MEDICINE CAN CAUSE ADDICTION, OVERDOSE, OR DEATH, especially in a child or other person using the medicine without a prescription. Selling or giving away 168 HR BuTrans 0.015 MG/HR Transdermal System is against the law.
The 168 HR BuTrans 0.015 MG/HR Transdermal System sublingual tablet should be placed under the tongue and allowed to dissolve. Do not chew the tablet or swallow it whole. If your doctor has prescribed more than 2 tablets per dose, place the correct number of tablets under your tongue at the same time and allow them to dissolve completely.
While using 168 HR BuTrans 0.015 MG/HR Transdermal System, you may need frequent blood tests to check your liver function.
If you need surgery, tell the surgeon ahead of time that you are using 168 HR BuTrans 0.015 MG/HR Transdermal System. You may need to stop using the medicine for a short time.
Wear a medical alert tag or carry an ID card stating that you take 168 HR BuTrans 0.015 MG/HR Transdermal System. Any medical care provider who treats you should know that you are being treated for narcotic addiction. Make sure your family members know you are using 168 HR BuTrans 0.015 MG/HR Transdermal System in case they need to speak for you during an emergency.
Do not stop using 168 HR BuTrans 0.015 MG/HR Transdermal System suddenly, or you could have unpleasant withdrawal symptoms. Ask your doctor how to safely stop using 168 HR BuTrans 0.015 MG/HR Transdermal System.
Store at room temperature away from moisture and heat.
Keep track of the amount of medicine used from each new bottle. 168 HR BuTrans 0.015 MG/HR Transdermal System is a drug of abuse and you should be aware if anyone is using your medicine improperly or without a prescription.
Do not keep leftover 168 HR BuTrans 0.015 MG/HR Transdermal System pills. Ask your pharmacist where to locate a drug take-back disposal program. If there is no take-back program, flush any unused pills down the toilet
Never crush or break a 168 HR BuTrans 0.015 MG/HR Transdermal System pill to inhale the powder or mix it into a liquid to inject the drug into your vein. This practice has resulted in death with the misuse of 168 HR BuTrans 0.015 MG/HR Transdermal System and similar prescription drugs.
Can 168 HR BuTrans 0.015 MG/HR Transdermal System be taken or consumed while pregnant?
Please visit your doctor for a recommendation as such case requires special attention.
Can 168 HR BuTrans 0.015 MG/HR Transdermal System be taken for nursing mothers or during breastfeeding?
Kindly explain your state and condition to your doctor and seek medical advice from an expert.
Reviews
Following the study conducted by gmedication.com on 168 HR BuTrans 0.015 MG/HR Transdermal System, the result is highlighted below. However, it must be clearly stated that the survey and result is based solely on the perception and impression of visitors and users of the website as well as consumers of 168 HR BuTrans 0.015 MG/HR Transdermal System. We, therefore, urge readers not to base their medical judgment strictly on the result of this study but on test/diagnosis duly conducted by a certified medical practitioners or physician.Patient reports
Patient reported useful
No survey data has been collected yetPatient reported side effects
No survey data has been collected yetPatient reported price estimates
No survey data has been collected yetPatient reported frequency of use
No survey data has been collected yetPatient reported doses
No survey data has been collected yetPatient reported time for results
No survey data has been collected yetPatient reported administration
No survey data has been collected yetPatient reported age
No survey data has been collected yetPatient reviews
There are no reviews yet. Be the first to write one! |
The information was verified by Dr. Vishal Pawar, MD Pharmacology